Form 4: CalciMedica Executive Eric W. Roberts Reports Stock Option Grant

Eric W. Roberts, Chief Business Officer of CalciMedica, reports the acquisition of stock options.

Summary

• Eric W. Roberts, Chief Business Officer of CalciMedica, filed a Form 4 on April 22, 2024, reporting a transaction on March 28, 2024.
• The transaction involved the acquisition of 77,500 employee stock options with an exercise price of $4.16.
• These options vest in equal monthly installments over four years, starting from the grant date.
• Following the transaction, Roberts directly owns 77,500 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules, such as the four-year monthly vesting described, are typical to ensure long-term alignment.
• Comparing the size of the grant to similar companies and executive roles would provide further context on its competitiveness.

Stakeholder Impact

• The stock option grant could incentivize the executive to improve company performance, benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates